Gide, Tuba N.
The University of Sydney · Melanoma Institute Australia
4 papers on CoChatORCID 0000-0003-2473-5565
Most cited papers
- Verified
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Gide, T. N., Quek, C., Menzies, A. M., Tasker, A. T., Shang, P., Holst, J., Madore, J., Lim, S. Y., Velickovic, R., Wongchenko, M., et al. (2019) · Cancer Cell
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 1,047
- Verified
Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersChemokine receptors and signaling
Cited by 790
- Verified
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
Lim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 381
- Verified
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
Long, G. V., Shklovskaya, E., Satgunaseelan, L., Mao, Y., da Silva, I. P., Perry, K. A., Diefenbach, R. J., Gide, T. N., Shivalingam, B., Buckland, M. E., et al. (2025) · Nature Medicine
Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 83
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free